Big Pharma Ramps Up Biotech M&A
Major pharmaceutical companies are increasingly acquiring biotech firms to fill pipeline gaps as high-value drug patents expire. This trend is creating a new wave of M&A activity, with a recent podcast highlighting that PE funds and strategic acquirers are driving a record pace of deals in Q1 2026. As one example, Community Health Systems is selling two hospitals for $112M to divest non-core assets.
The so-called "patent cliff" is a primary driver of this M&A surge, with major pharmaceutical companies facing an estimated $200 billion to $400 billion in revenue loss by 2030 from expiring patents on blockbuster drugs. This revenue gap is intensifying the pressure on companies to acquire external assets rather than relying solely on in-house R&D. This trend was underscored by a significant uptick in deal value in 2025, which reached approximately $240 billion, an 81% increase from the previous year. Rather than a high volume of small deals, the market shifted towards fewer, higher-impact transactions, with the average deal size more than doubling compared to 2024. Key examples from 2025 include Johnson & Johnson's $14.6 billion acquisition of Intra-Cellular Therapies to gain its schizophrenia and bipolar disorder drug, Caplyta. Merck also made significant moves to offset the upcoming 2028 patent expiration of its cancer immunotherapy drug Keytruda, acquiring Verona Pharma for $10 billion and Cidara Therapeutics for $9.2 billion. The battle for promising assets has become increasingly competitive, as seen in the bidding war for obesity drug developer Metsera. Pfizer ultimately secured the deal for approximately $10 billion after an initial offer of $4.9 billion was challenged by a rival bid from Novo Nordisk. This highlights the premium companies are willing to pay for assets in high-growth therapeutic areas like cardiometabolics, oncology, and immunology. Private equity firms are playing a significant role, adding to the more than $1.2 trillion in M&A capital held by biopharma companies. While PE firms' share of deal value held steady at around 25% in 2025, they are increasingly using structured financing like royalties and minority stakes to help bridge biotech firms from late-stage development to commercialization. The focus of these acquisitions is sharply on de-risked and late-stage assets that can provide near-term revenue. In fact, deals focused on growth and late-stage assets have more than doubled as a percentage of all deals since the early 2010s. This strategic shift towards buying innovation is expected to continue, with analysts forecasting a 15% growth in both M&A volume and total deal value in 2026.
